Venkataramanujan Srinivasan

TL;DR: The evidence concerning melatonin receptors and signal transduction pathways in various organs is reviewed and their relevance to circadian physiology and pathogenesis of certain human diseases, with a focus on the brain, the cardiovascular and immune systems, and cancer is considered.

TL;DR: The dim light melatonin onset or DLMO marker is useful for determining whether an individual is entrained to a 24-h light/dark (LD) cycle or is in a free-running state, and is also useful for assessing phase delays or advances of rhythms in entrained individuals.

TL;DR: Clinical trials employing melatonin doses in the range of 50–100 mg/day are warranted before the relative merits of the melatonin analogs versus melatonin can be settled, in view of the higher binding affinities, longest half‐life and relative higher potencies of the different melatonin agonists.

TL;DR: The role of melatonin in the pathophysiology of bipolar disorder and SAD is discussed and bright light treatment, that suppresses melatonin production, is effective in treating bipolar affective disorder andSAD, winter type.

TL;DR: The physiological surge of melatonin at night is considered a “natural restraint” on tumor initiation, promotion, and progression and protects hematopoietic precursors from the toxic effect of anticancer chemotherapeutic drugs.